Urine biomarkers in type 2 diabetes mellitus with or without microvascular complications.
Humans
Diabetes Mellitus, Type 2
/ urine
Biomarkers
/ urine
Male
Female
Middle Aged
Diabetic Retinopathy
/ urine
Albuminuria
/ urine
Aged
Creatinine
/ urine
Alpha-Globulins
/ urine
beta 2-Microglobulin
/ urine
Cystatin C
/ urine
Retinol-Binding Proteins
/ urine
Diabetic Nephropathies
/ urine
Adult
Diabetic Angiopathies
/ urine
Lipocalin-2
/ urine
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
received:
22
11
2023
accepted:
20
06
2024
revised:
18
06
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
10
7
2024
Statut:
epublish
Résumé
To investigate the distribution of nine (9) urine biomarkers in people living with type 2 diabetes mellitus (T2DM), with or without microvascular complications. In total, 407 people with T2DM were enrolled from 2021 to 2022. According to diabetic retinopathy (DR) and urinary albumin-creatinine ratio (UACR), the 407 people were divided into four (4) groups, DR(-)UACR(-), DR(+)UACR(-), DR(-)UACR(+), and DR( + )UACR(+). In addition, 112 healthy volunteers were enrolled during the same period. The nine (9) urine markers included α1-microglobulin (u-α1MG), immunoglobulin G (u-IgG), neutrophil gelatinase-associated lipid carrier protein (u-NGAL), cystatin C (u-CysC), retinol-binding protein (u-RBP), β2-microglobulin (u-β2MG), N-acetyl-β-D-glucosaminidase (u-NAG), transferrin (u-Trf), and collagen type IV (u-Col). For each marker, the respective level of 97.5 percentile in healthy volunteers was taken as an upper reference limit. Among the 407 people, 248 individuals (61%) were DR(-)UACR(-), 100 (25%) were DR(-)UACR(+), 37 (9%) were DR(+)UACR(-), and 22 (5%) were DR(+)UACR(+). The u-NAG/Cr biomarker level showed a significant difference between healthy participants and people with T2DM. In the DR(-)UACR(-)group, u-Trf/Cr showed the highest positive rate (21.37%), followed by u-IgG/Cr (14.52%); u-NAG/Cr (10.48%); u-β2MG/Cr (4.44%); u-CysC/Cr (4.03%); u-NGAL/Cr (4.03%); u-RBP/Cr (2.82%); u-α1MG/Cr (2.42%); 17.34% of people with T2DM showed multiple biomarkers positive (≥2 biomarkers). The positive rates of one biomarker (21.33%) and two biomarkers (18.67%) in people who have less than five (5) years of T2DM were almost close to those of the DR(-)UACR(-) group (21.37%, and 12.10%, respectively). Renal tubule biomarkers may be used as an indicator in the early detection and monitoring of renal injury in diabetes mellitus. The u-NAG biomarker should be measured for the people with T2DM of the first-time diagnosis.
Identifiants
pubmed: 38987257
doi: 10.1038/s41387-024-00310-5
pii: 10.1038/s41387-024-00310-5
doi:
Substances chimiques
Biomarkers
0
Creatinine
AYI8EX34EU
Alpha-Globulins
0
alpha-1-microglobulin
0
beta 2-Microglobulin
0
Cystatin C
0
Retinol-Binding Proteins
0
Lipocalin-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Informations de copyright
© 2024. The Author(s).
Références
Aldemir O, Turgut F, Gokce C. The association between methylation levels of targeted genes and albuminuria in patients with early diabetic kidney disease. Ren Fail. 2017;39:597–601.
doi: 10.1080/0886022X.2017.1358180
pubmed: 28805547
pmcid: 6446175
Cefalu, William T, Berg, Gebel E, Saraco, Mindy, et al. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S124–S138. (42-Suppl.1).
doi: 10.2337/dc19-S011
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
doi: 10.1016/j.diabres.2019.107843
pubmed: 31518657
Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of diabetic kidney disease: current and future. Diabetes Metab J. 2021;45:11–26.
doi: 10.4093/dmj.2020.0217
pubmed: 33508907
pmcid: 7850867
Jiang X, Zhang Q, Wang H-B, Cui X-F, Liu R. Associations of urinary, glomerular, and tubular markers with the development of diabetic kidney disease in type 2 diabetes patients. J Clin Lab Anal. 2018;32:e22191.
doi: 10.1002/jcla.22191
pubmed: 28236320
Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.
doi: 10.1001/jama.2016.10924
pubmed: 27532915
pmcid: 5444809
Chen C, Wang C, Hu C, Han Y, Zhao L, Zhu X, et al. Normoalbuminuric diabetic kidney disease. Front Med. 2017;11:310–8.
doi: 10.1007/s11684-017-0542-7
pubmed: 28721497
Heyman SN, Raz I, Dwyer JP, Sibony RW, Lewis JB, Abassi Z. Diabetic proteinuria revisited: updated physiologic perspectives. Cells. 2022;11:2917.
doi: 10.3390/cells11182917
pubmed: 36139492
pmcid: 9496872
Kishore L, Kaur N, Singh R. Distinct biomarkers for early diagnosis of diabetic nephropathy. Curr Diabetes Rev. 2017;13:598–605.
doi: 10.2174/1573399812666161207123007
pubmed: 27924722
Ix JH, Shlipak MG. The promise of tubule biomarkers in kidney disease: a review. Am J Kidney Dis. 2021;78:719–27.
doi: 10.1053/j.ajkd.2021.03.026
pubmed: 34051308
pmcid: 8545710
Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Bonventre JV, Sabbisetti V, et al. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia. 2015;58:188–98.
doi: 10.1007/s00125-014-3389-3
pubmed: 25316431
Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes care. 2021;44:S15–S33.
doi: 10.2337/dc21-S002
Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18:117–24.
doi: 10.2174/1570161117666190502103733
pubmed: 31057114
Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 2018;125:1608–22.
doi: 10.1016/j.ophtha.2018.04.007
pubmed: 29776671
Zhang C, Xu S, Wang X. Performance evaluation of the reagents for 10 markers of renal injury in urine. Chin J Clin Lab Sci. 2022;40:763–7.
Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2023;69:808–68.
doi: 10.1093/clinchem/hvad080
pubmed: 37473453
Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44:260–77.
doi: 10.1111/ceo.12696
pubmed: 26716602
Mima A. A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther. 2022;39:3488–500.
doi: 10.1007/s12325-022-02223-0
pubmed: 35751762
An C, Akankwasa G, Liu J, Wang D, Cheng G, Zhang J, et al. Urine markers of renal tubular injury in idiopathic membranous nephropathy: A cross sectional study. Clin Chim Acta. 2019;492:7–11.
doi: 10.1016/j.cca.2019.01.015
pubmed: 30684459
Han E, Kim M-K, Lee Y-H, Kim HS, Lee B-W. Association between nonalbumin proteinuria and renal tubular damage of N-acetyl-β-d-glucosaminidase and its clinical relevance in patients with type 2 diabetes without albuminuria. J Diabetes Complications. 2019;33:255–60.
doi: 10.1016/j.jdiacomp.2018.09.010
pubmed: 30236543
Djukanović L, Djordjević V, Ležaić V, Cukuranović R, Marić I, Bukvić D, et al. Urinary protein patterns in patients with Balkan endemic nephropathy. Int Urol Nephrol. 2013;45:1661–9.
doi: 10.1007/s11255-013-0499-7
pubmed: 23877662
Berg UB, Bohman SO, Widstam-Attorps U. Renal histological changes in relation to renal function and urinary protein excretion in IgA nephropathy. Arch Dis Child. 1991;66:593–7.
doi: 10.1136/adc.66.5.593
pubmed: 2039248
pmcid: 1792954
Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, et al. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes care. 2004;27:1176–81.
doi: 10.2337/diacare.27.5.1176
pubmed: 15111541
Meng C, Chen J, Sun X, Guan S, Zhu H, Qin Y, et al. Urine immunoglobin G greater Than 2.45 mg/L has a correlation with the onset and progression of diabetic kidney disease: a retrospective cohort study. J Personalized Med. 2023;13:452.
doi: 10.3390/jpm13030452
Narita T, Fujita H, Koshimura J, Meguro H, Kitazato H, Shimotomai T, et al. Glycemic control reverses increases in urinary excretions of immunoglobulin G and ceruloplasmin in type 2 diabetic patients with normoalbuminuria. Horm Metab Res. 2001;33:370–8.
doi: 10.1055/s-2001-15415
pubmed: 11456288
Narita T, Kitazato H, Koshimura J, Suzuki K, Murata M, Ito S. Effects of protein meals on the urinary excretion of various plasma proteins in healthy subjects. Nephron. 1999;81:398–405.
doi: 10.1159/000045323
pubmed: 10095175
Narita T, Hosoba M, Kakei M, Ito S. Increased urinary excretions of immunoglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care. 2006;29:142–4.
doi: 10.2337/diacare.29.01.06.dc05-1063
pubmed: 16373913
Li A, Yi B, Liu Y, Wang J, Dai Q, Huang Y, et al. Urinary NGAL and RBP are biomarkers of normoalbuminuric renal insufficiency in type 2 diabetes mellitus. J Immunol Res. 2019;2019:5063089.
doi: 10.1155/2019/5063089
pubmed: 31637265
pmcid: 6766169
Zhang D, Ye S, Pan T. The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes. PeerJ. 2019;7:e7079.
doi: 10.7717/peerj.7079
pubmed: 31218128
pmcid: 6568248